Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life-Reference-Cited by-同舟云学术

Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life

Published:2016-07-13 Issue:12 Volume:23 Page:950-954
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Willemse S. B.¹,Baak L. C.²,Kuiken S. D.³,Sluys Veer A.²,Lettinga K. D.⁴,Meer J. T. M.⁵,Depla A. C. T. M.⁶,Tuynman H.⁶,Nieuwkerk C. M. J.⁷,Schinkel C. J.⁸,Kwa D.⁹,Reesink H. W.¹,Valk M.¹⁵

Affiliation:

1. Department of Gastroenterology and Hepatology Academic Medical Center Amsterdam the Netherlands

2. Department of Gastroenterology and Hepatology Onze Lieve Vrouwe Gasthuis locatie Oost Amsterdam the Netherlands

3. Department of Gastroenterology and Hepatology Onze Lieve Vrouwe Gasthuis locatie West Amsterdam the Netherlands

4. Department of Internal Medicine Onze Lieve Vrouwe Gasthuis locatie West Amsterdam the Netherlands

5. Department of Infectious Diseases CINIMA Academic Medical Center Amsterdam the Netherlands

6. Department of Gastroenterology and Hepatology Slotervaart Ziekenhuis Amsterdam the Netherlands

7. Department of Gastroenterology and Hepatology VU Medical Center Amsterdam the Netherlands

8. Department of Medical Microbiology Section of Clinical Virology Academic Medical Center Amsterdam the Netherlands

9. Department of Medical Microbiology Onze Lieve Vrouwe Gasthuis Amsterdam the Netherlands

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12567

Reference21 articles.

1. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.

2. Global epidemiology and genotype distribution of the hepatitis C virus infection

3. EASL Recommendations on Treatment of Hepatitis C 2014

4. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

5. SVR results of a once‐daily regimen of simeprevir (TMC435) plus sofosbuvir (GS‐7977) with or without ribavirin in cirrhotic and non‐cirrhotic HCV genotype 1 treatment‐naïve and prior null responder patients: the COSMOS study;Jacobson I;Hepatology,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents;International Urology and Nephrology;2019-10-14

2. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort;BMC Infectious Diseases;2019-04-02

3. Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu;European Journal of Gastroenterology & Hepatology;2019-02

4. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients;European Geriatric Medicine;2019-01-24

5. Treatment of hepatitis C virus genotype 4 in the DAA era;Virology Journal;2018-11-22